{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:10:35Z","timestamp":1790745035226,"version":"4.1.0"},"reference-count":123,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["DEQ20130326467"],"award-info":[{"award-number":["DEQ20130326467"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-CE14-0030, ANR-13-BSV1-0021"],"award-info":[{"award-number":["ANR-16-CE14-0030, ANR-13-BSV1-0021"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00954","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T23:43:49Z","timestamp":1502408629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma"],"prefix":"10.3389","volume":"8","author":[{"given":"Anna","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelilah","family":"Wakkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Blin-Wakkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2012-06-430645","article-title":"Darwinian evolution and tiding clones in multiple myeloma","volume":"120","author":"Bahlis","year":"2012","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","article-title":"Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma","volume":"120","author":"Walker","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1084\/jem.178.3.1023","article-title":"The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell","volume":"178","author":"Billadeau","year":"1993","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple myeloma","volume":"2002","author":"Anderson","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nm1417","article-title":"Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells","volume":"12","author":"Kollet","year":"2006","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.20110994","article-title":"Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow","volume":"209","author":"Mansour","year":"2012","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/cr.2011.21","article-title":"Osteoclast activity modulates B-cell development in the bone marrow","volume":"21","author":"Mansour","year":"2011","journal-title":"Cell Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.4049\/jimmunol.0803897","article-title":"Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells","volume":"182","author":"Kiesel","year":"2009","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/jcp.22411","article-title":"T cell suppression by osteoclasts in vitro","volume":"226","author":"Grassi","year":"2011","journal-title":"J Cell Physiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/jbmr.2868","article-title":"Inflammatory osteoclasts prime TNF\u03b1-producing CD4(+) T cells and express CX3 CR1","volume":"31","author":"Ib\u00e1\u00f1ez","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"crossref","unstructured":"MansourA MarseilleUniversity of Aix MarseilleEmerging Roles of Osteoclasts in the Modulation of bone Microenvironment in Multiple Myeloma2017","DOI":"10.3389\/fimmu.2017.00954"},{"key":"B22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1309\/74R4-TB90-BUWH-27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1111\/febs.12180","article-title":"Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma","volume":"280","author":"Reijmers","year":"2013","journal-title":"FEBS J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1096\/fj.02-0205com","article-title":"Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption","volume":"17","author":"Sun","year":"2003","journal-title":"FASEB J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1126\/science.1188385","article-title":"High speed scintillation autoradiography","volume":"190","author":"Durie","year":"1975","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1002\/jcp.25351","article-title":"Current controversies in the management of myeloma bone disease","volume":"231","author":"Silbermann","year":"2016","journal-title":"J Cell Physiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/cncr.26467","article-title":"18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review","volume":"118","author":"van Lammeren-Venema","year":"2012","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrrheum.2011.23","article-title":"Advances in osteoclast biology: old findings and new insights from mouse models","volume":"7","author":"Edwards","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fendo.2015.00041","article-title":"Coupling signals between the osteoclast and osteoblast: how are messages transmitted between these temporary visitors to the bone surface?","volume":"6","author":"Sims","year":"2015","journal-title":"Front Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1006\/excr.1998.4320","article-title":"Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts\/stromal cells","volume":"247","author":"Jimi","year":"1999","journal-title":"Exp Cell Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jbmr.5650070502","article-title":"Interleukin-6: an osteotropic factor?","volume":"7","author":"Roodman","year":"1992","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/gutjnl-2014-306947","article-title":"Bone marrow Th17 TNF\u03b1 cells induce osteoclast differentiation, and link bone destruction to IBD","volume":"64","author":"Ciucci","year":"2015","journal-title":"Gut"},{"key":"B46","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3389\/fimmu.2015.00640","article-title":"Osteoimmune interactions in inflammatory bowel disease: central role of bone marrow Th17 TNF\u03b1 cells in osteoclastogenesis","volume":"6","author":"Wakkach","year":"2015","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"B53","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2013.385","article-title":"Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma","volume":"28","author":"Silbermann","year":"2014","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2004-01-0041","article-title":"Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment","volume":"104","author":"Rivollier","year":"2004","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1182\/blood-2008-01-132787","article-title":"Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts","volume":"112","author":"Wakkach","year":"2008","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.drudis.2016.04.022","article-title":"Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases","volume":"21","author":"Laperine","year":"2016","journal-title":"Drug Discov Today"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17\u2013producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjh.12333","article-title":"Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation","volume":"161","author":"Tucci","year":"2013","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0304-3835(83)90145-3","article-title":"Direct bone resorbing activity of murine myeloma cells","volume":"19","author":"McDonald","year":"1983","journal-title":"Cancer Lett"},{"key":"B66","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1365-2141.2005.05710.x","article-title":"Functional osteoclast-like transformation of cultured human myeloma cell lines","volume":"130","author":"Calvani","year":"2005","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/path.2078","article-title":"Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?","volume":"211","author":"Andersen","year":"2007","journal-title":"J Pathol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.exphem.2017.01.008","article-title":"The evolving view of the hematopoietic stem cell niche","volume":"50","author":"Beerman","year":"2017","journal-title":"Exp Hematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.abb.2014.06.032","article-title":"Roles of osteoclasts in the control of medullary hematopoietic niches","volume":"561","author":"Blin-Wakkach","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"B71","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4049\/jimmunol.1302713","article-title":"Inhibition of bone remodeling in young mice by bisphosphonate displaces the plasma cell niche into the spleen","volume":"193","author":"Teufel","year":"2014","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/asheducation-2004.1.237","article-title":"Multiple myeloma","volume":"2004","author":"Harousseau","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B75","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0012-1606(03)00299-9","article-title":"Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones","volume":"261","author":"Chiusaroli","year":"2003","journal-title":"Dev Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e35981","DOI":"10.1371\/journal.pone.0035981","article-title":"Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent","volume":"7","author":"Feyler","year":"2012","journal-title":"PLoS One"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br J Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3109\/10428194.2013.825905","article-title":"Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"37931","DOI":"10.18632\/oncotarget.9270","article-title":"Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma","volume":"7","author":"Binsfeld","year":"2016","journal-title":"Oncotarget"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e48871","DOI":"10.1371\/journal.pone.0048871","article-title":"Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells","volume":"7","author":"Zhuang","year":"2012","journal-title":"PLoS One"},{"key":"B91","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/leu.2013.220","article-title":"Association of response endpoints with survival outcomes in multiple myeloma","volume":"28","author":"Lonial","year":"2014","journal-title":"Leukemia"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"B94","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/cncr.28481","article-title":"The effects of bortezomib on bone disease in patients with multiple myeloma","volume":"120","author":"Mohty","year":"2014","journal-title":"Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Roccaro","year":"2006","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.leukres.2008.02.019","article-title":"Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions","volume":"32","author":"Boissy","year":"2008","journal-title":"Leuk Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"B100","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.leukres.2008.07.028","article-title":"Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6","volume":"33","author":"Hongming","year":"2009","journal-title":"Leuk Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"172458","DOI":"10.1155\/2015\/172458","article-title":"Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling","volume":"2015","author":"Accardi","year":"2015","journal-title":"Biomed Res Int"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"key":"B105","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives","volume":"21","author":"Dimopoulos","year":"2003","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"Gorgun","year":"2010","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","article-title":"Lenalidomide mode of action: linking bench and clinical findings","volume":"24","author":"Davies","year":"2010","journal-title":"Blood Rev"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":"Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T17:30:08Z","timestamp":1602696608000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":123,"alternative-id":["10.3389\/fimmu.2017.00954"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00954","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]},"article-number":"954"}}